Our merger with Aceragen is a key development in our goal to help patients with rare diseases get more from life.
Learn MoreDURHAM, N.C. and EXTON, Pa., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Aceragen, Inc. (Nasdaq: ACGN) a… Read more
Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq… Read more
EXTON, Pa. and DURHAM, N.C. , Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc.… Read more